The Streptococcus Agalactiae Complement Interfering Protein Combines Multiple Complement-Inhibitory Mechanisms by Interacting with Both C4 and C3 Ligands.

Group B Streptococcus (GBS) colonizes the human lower intestinal and genital tracts and constitutes a major threat to neonates from pregnant carrier mothers and to adults with underlying morbidity. The pathogen expresses cell‐surface virulence factors that enable cell adhesion and penetration and that counteract innate and adaptive immune responses. Among these, the complement interfering protein (CIP) was recently described for its capacity to interact with the human C4b ligand and to interfere with the classical‐ and lectin‐complement pathways. In the present study, we provide evidence that CIP can also interact with C3, C3b, and C3d. Immunoassay‐based competition experiments showed that binding of CIP to C3d interferes with the interaction between C3d and the complement receptor 2/cluster of differentiation 21 (CR2/CD21) receptor on B cells. By B‐cell intracellular signaling assays, CIP was confirmed to down‐regulate CR2/CD21‐dependent B‐cell activation. The CIP domain involved in C3d binding was mapped via hydrogen deuterium exchange–mass spectrometry. The data obtained reveal a new role for this GBS polypeptide at the interface between the innate and adaptive immune responses, adding a new member to the growing list of virulence factors secreted by gram‐positive pathogens that incorporate multiple immunomodulatory functions.—Giussani, S., Pietrocola, G., Donnarumma, D., Norais, N., Speziale, P., Fabbrini, M., Margarit, I. The Streptococcus agalactiae complement interfering protein combines multiple complement‐inhibitory mechanisms by interacting with both C4 and C3 ligands. FASEB J. 33,4448–4457 (2019). www.fasebj.org